As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities for comprehensive protein biomarker discovery using Olink® Target technology.
The GeoMx Whole Transcriptome Atlas (WTA) empowers to explore biology accross a tissue. The human whole transcriptome (over 18,000 protein-coding human genes) is measured in each region of interest to uncover biological changes at specific locations of the tissue.
The GeoMx Whole Transcriptome Atlas delivers the maximum amount of sensitivity and confidence in each transcript through its unique probe architecture. The WTA profiles over 18,000 protein-coding human genes based on the human gene nomenclature committee (HUGO1) database cross-referenced with available mRNA sequences in the National Center for Biotechnology’s Information (NCBI) RefSeq database.
The WTA then allows to explore pathways across the whole transcriptome in defined regions of interest.
- Whole transcriptome coverage with probes specific to protein coding mRNA sequences
- Compatible with common sample types such as formalin-fixed paraffin embedded (FFPE) or fresh frozen (FF) tissue and across all human tissues types
- Superior sensitivity to detect 1000s of unique human genes in <50 μm regions
- Robust performance across sample types including FFPE with high concordance with RNA-seq and RNAscope™
- Map single cell RNA-seq populations to their tissue location
The GeoMx Whole Transcriptome Atlas delivers the maximum amount of sensitivity and confidence in each transcript through its unique probe architecture. The WTA profiles over 18,000 protein-coding human genes based on the human gene nomenclature committee (HUGO1) database cross-referenced with available mRNA sequences in the National Center for Biotechnology’s Information (NCBI) RefSeq database.
The WTA then allows to explore pathways across the whole transcriptome in defined regions of interest.
Learn about out Digitial Spatial Profiling (DSP) services
The Cancer Transcriptome Atlas (CTA) is designed for comprehensive profiling of the tumor biology, tumor microenvironment, and the immune response. It covers the RNA expression of over 1,800 genes simultaneously with spatial resolution in any region of interest from a single tissue section.
The CTA assay is compatible with RNAscope® and antibody visualization markers. It can also be supplemented with up to 60 additional targets of interest.
- Extensive coverage of the immune response, tissue microenvironment, tumor biology, and genes from clinically relevant genes sets such as tumor inflammation
- Spatial measurement of single cell signatures with high sensitivity and dynamic range
- Inclusion of genes for the Tumor Inflammation Signature, PAM50 and other clinical signatures
- Over 100 pathways to explore all aspects of cancer and tumor biology
Learn about out spatial transcriptomics services
Comprehensively Annotated Pathways in the CTA
| Adaptive Immunity | | Cell Function | | Signaling Pathways |
| T cells B cells | Apoptosis | AMPK Signaling | ||
| TCR & BCR Signaling | Autophagy | Androgen Signaling | ||
| Cancer Antigens | Cell Adhesion & Motility | EGFR Signaling | ||
| MHC Class I & II Antigen Presentation | Cell Cycle | ERBB2 Signaling | ||
| T-cell Checkpoints | Cilium Assembly | Estrogen Signaling | ||
| TH1, TH2, TH9, Th17, and Treg Differentiation | Differentiation | FGFR Signaling | ||
| DNA Damage Repair | FoxO Signaling | |||
| Innate Immunity | EMT | GPCR Signaling | ||
| Complement System | Endocytosis | Hedgehog Signaling | ||
| Dendritic Cells | Epigenetic Modification | HIF1 Signaling | ||
| DNA & RNA Sensing | Immortality & Stemness | Insulin Signaling | ||
| Glycan Sensing | Ion Transport | JAK-STAT Signaling | ||
| Host Defense Peptides | Lysosome | MAPK Signaling | ||
| Inflammasomes | Oxidative Stress | MET Signaling | ||
| Myeloid Inflammation | Phagocytosis | mTOR Signaling | ||
| Neutrophil Degranulation | Proteotoxic Stress | Myc | ||
| NK Activity | RNA Processing | NO Signaling | ||
| NLR Signaling | Senescence | Notch Signaling | ||
| RAGE Signaling | p53 Signaling | |||
| TLR Signaling | Metabolism | PDGF Signaling | ||
| Amino Acid Synthesis & Transport | PI3K-Akt Signaling | |||
| Immune Response | Arginine & Glutamine Metabolism | PPAR Signaling | ||
| Chemokine Signaling | Fatty Acid Oxidation & Synthesis | Purinergic Signaling | ||
| Cytotoxicity | Glycolysis & Glucose Transport | Retinoic Acid Signaling | ||
| IL-1, IL-2, IL-6 & IL-17 Signaling | Glycosylation | TGF-beta Signaling | ||
| Immune Exhaustion | IDH1/2 | VEGF Signaling | ||
| Interferon Response Genes | Lipid Metabolism | Wnt Signaling | ||
| Lymphocyte Regulation & Trafficking | Mitochondrial Metabolism / TCA | |||
| NF-kB Signaling | Nucleotide Synthesis | Physiology & Disease | ||
| Other Interleukin Signaling | Pentose Phosphate | Angiotensin System | ||
| Prostaglandin Inflammation | Tryptophan & Kynurenine Metabolism | Circadian Clock | ||
| TNF Signaling | Vitamin & Cofactor Metabolism | Drug Resistance | ||
| Type I, II, & III Interferon Signaling | | Glioma | ||
| | Leukemia | |||
| Matrix Remodeling and Metastasis | ||||
| Melanoma | ||||
| Neuroendocrine Function | ||||
| Prostate Cancer |
Read our latest peer-reviewed publication, titled Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.
Soft Tissue Sarcoma (STS) is known to be refractory to current cancer immunotherapies including the PD1 immune checkpoint inhibitor (ICI) (Toulmonde et al., 2018), thus claiming the development of novel therapeutic strategies aiming at improving the current clinical benefit.
In the era of immuno-oncology, it’s critical to unravel mechanisms of action underlying sensitivity or resistance to current immunotherapies in order to identify predictive biomarkers of response and then discover novel actionable therapeutic targets.
We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there!
Drawing on our expertise in IHC and IHF assays, we have developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets.
Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement.
Discover our latest study, titled Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Discover our latest article, published in Frontiers in Immunology.